JP Morgan Chase
ATHE

JP Morgan Chase’s Alterity Therapeutics ATHE Stock Holding History

JP Morgan Chase’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-53
Closed -$184 – 7060
2025
Q1 		$184 Buy
+53
New +$203 ﹤0.01% 6808
2020
Q2 		– Sell
-10
Closed – – 5358
2020
Q1 		$0 Buy
+10
New +$69 ﹤0.01% 5281

Other funds holding ATHE

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
TLCM
Twin Lakes Capital Management Redwood Shores, California $220M AUM 31.75% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $3.28B AUM 23.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

JP Morgan Chase's ATHE Position: Q2 2025 in Review

JP Morgan Chase sold out of Alterity Therapeutics (ATHE) in Q2 2025, closing a stake of 53 shares — an estimated $184 sold.

JP Morgan Chase first reported a position in ATHE in Q1 2020 and held it in 2 quarters. The position peaked at $184 in Q1 2025. 11 funds tracked by Wall St. Rank hold ATHE as of Q2 2025.

  • JP Morgan Chase reported no remaining Alterity Therapeutics position as of Q2 2025 after selling out during the quarter.
  • JP Morgan Chase sold 53 Alterity Therapeutics shares in Q2 2025, an estimated $184.
  • JP Morgan Chase first reported a position in Alterity Therapeutics in Q1 2020 and held it in 2 quarters.
  • JP Morgan Chase's Alterity Therapeutics position peaked at $184 in Q1 2025.
  • 11 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.